Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Scoops Up UK's Mitochondria-Focused Biotech Nanna
April 22, 2020
- Sawai Curbing Shipments for 2 More Drugs after Nichi-Iko’s Massive Recalls
April 21, 2020
- Sumitomo Dainippon Chair Sees No Need for Further Consolidation among Japan Drug Makers
April 21, 2020
- Otsuka Grabs Japan Rights to Esperion’s Cholesterol Drug
April 21, 2020
- JCR Closes ArmaGen Buyout, Gaining IP Rights on Blood-Brain Barrier-Penetrating Technology
April 21, 2020
- Otsuka, Meiji Put Off Earnings Announcement amid COVID-19 Outbreak
April 21, 2020
- Japan Generic Makers’ New Grad Hiring Logs 1st Increase Since FY2016
April 20, 2020
- Some Drug Makers Rejuvenating Workforce by Boosting New Hires after Job Cuts: Jiho Survey
April 20, 2020
- Towa, Osaka Psychiatric Medical Center Pair Up on Novel Biomarker Research for AD
April 20, 2020
- Konica Minolta’s US Subsidiary to Launch PCR Testing Platform
April 20, 2020
- Takeda, Tohoku University Ink Joint Research Pact on Whole Genome Sequencing
April 20, 2020
- Big 3 Generic Makers to Discontinue Procaterol Tablets as API Procurement Stalls
April 17, 2020
- Sunovion’s Novel Schizophrenia Med Smashes Primary Goals in US PII Study
April 17, 2020
- Novartis Japan Staffer Infected with Coronavirus
April 16, 2020
- Vibegron Prescription Soars after 14-Day Limit Lifted, Triggering Shipment Curbs
April 16, 2020
- Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief
April 16, 2020
- J&J’s TachoSil Deal Dropped on Antitrust Issues; Takeda Mum on Future Plan
April 16, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- PeptiDream Ties Up with PeptiGrowth on Development of Peptide Alternatives
April 16, 2020
- Kyowa Kirin Snags Global Rights to MEI’s Blood Cancer Drug in Expanded Deal
April 15, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…